Philip Hemme: LinkedIn Content Strategy & Writing Style

Here’s what really mattered in 2025, to me 🤓 1. Abivax 🇫🇷 hits a Phase 3 home-run in inflammatory bowel disease, sending its stock through the roof (+1700% YTD). The biggest jump of any European s…

RECORDING: Fredrik Tiberg has built one of the best biotechs you may have never heard of: Camurus 🇸🇪 At least that’s what I realized when preparing for the interview. We talked about the journey…

Here’re the most important news from the biggest biotech conference of the year, from Union Square in the heart of San Francisco: Nothing 🙃 Literally zero major news drops (no upfront or M&A >$100M…

EPISODE: Beginning of 2025, Sten announced Cereno Scientific’s positive Phase 2a results. He’s now moving forward with a global Ph2b trial. “We’ve got this data [in PAH], we’ve got the fast-track, th…

EPISODE: Pascal has brought two first-in-class cell therapies to patients. Now, he’s helping and investing in others to do the same. He also relates how European biotechs and investors missed out on…

EPISODE (#50 🥳): In 2023, Alessandro became CEO of the 45+ year-old Transgene. Today, it’s a leader in cancer vaccines, with strong Ph1/2 data. Despite the industry’s difficult history with cancer v…